183 related articles for article (PubMed ID: 22712479)
41. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
42. Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors.
Higuchi M; Suzuki H; Gotoh M
PET Clin; 2016 Jan; 11(1):47-55. PubMed ID: 26590443
[TBL] [Abstract][Full Text] [Related]
43. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
Culverwell AD; Chowdhury FU; Scarsbrook AF
Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
[TBL] [Abstract][Full Text] [Related]
45. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning.
Blokhuis TJ; van der Schaaf MC; van den Tol MP; Comans EF; Manoliu RA; van der Sijp JR
Scand J Gastroenterol Suppl; 2004; (241):93-7. PubMed ID: 15696856
[TBL] [Abstract][Full Text] [Related]
46. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
47. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
48. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
49. Recurrent hepatic epithelioid hemangioendothelioma: detection by FDG PET/CT.
Lin E; Agoff N
Clin Nucl Med; 2007 Dec; 32(12):949-51. PubMed ID: 18030050
[TBL] [Abstract][Full Text] [Related]
50. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinom.
Han AR; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Hepatogastroenterology; 2009; 56(93):1111-6. PubMed ID: 19760952
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis.
Zhang C; Chen Y; Xue H; Zheng P; Tong J; Liu J; Sun X; Huang G
Int J Cancer; 2009 Jan; 124(1):167-73. PubMed ID: 18844237
[TBL] [Abstract][Full Text] [Related]
52. The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.
Nielsen K; Scheffer HJ; Pieters IC; van Tilborg AA; van Waesberghe JH; Oprea-Lager DE; Meijerink MR; Kazemier G; Hoekstra OS; Schreurs HW; Sietses C; Meijer S; Comans EF; van den Tol PM
BMC Med Imaging; 2014 Aug; 14():27. PubMed ID: 25103913
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
54. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET.
Finkelstein SE; Fernandez FG; Dehdashti F; Siegel BA; Hawkins WG; Linehan DC; Strasberg SM
J Hepatobiliary Pancreat Surg; 2008; 15(5):483-7. PubMed ID: 18836801
[TBL] [Abstract][Full Text] [Related]
55. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
Strasberg SM; Dehdashti F
J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
[TBL] [Abstract][Full Text] [Related]
56. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
57. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review.
Maffione AM; Lopci E; Bluemel C; Giammarile F; Herrmann K; Rubello D
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):152-63. PubMed ID: 25319712
[TBL] [Abstract][Full Text] [Related]
59. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
60. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]